BioCorRx (BICX) Common Equity (2010 - 2026)

BioCorRx (BICX) has 17 years of Common Equity data on file, last reported at -$11.5 million in Q1 2026.

• Quarterly Common Equity rose 2.98% year-over-year to -$11.5 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$11.5 million (up 2.98% YoY) and the FY2025 annual result came in at -$11.2 million, up 9.16% from the prior year.
• Common Equity slipped to -$11.5 million in Q1 2026 per BICX's latest filing, from -$11.2 million in the prior quarter.
• The five-year high for Common Equity was -$6.8 million in Q1 2022, with the low at -$12.4 million in Q3 2025.
• Average Common Equity over 5 years is -$10.0 million, with a median of -$10.4 million recorded in 2023.
• Year-over-year, Common Equity sank 93.72% in 2022 and advanced 9.16% in 2025.
• BioCorRx's Common Equity stood at -$8.2 million in 2022, then declined by 21.35% to -$10.0 million in 2023, then dropped by 24.14% to -$12.4 million in 2024, then grew by 9.16% to -$11.2 million in 2025, then declined by 2.02% to -$11.5 million in 2026.
• Business Quant data shows BICX's Common Equity at -$11.5 million in Q1 2026, -$11.2 million in Q4 2025, and -$12.4 million in Q3 2025.